A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of HSK21542 Injection in Maintenance Hemodialysis Patients With Chronic Kidney Disease-associated Pruritus
Latest Information Update: 07 Nov 2023
At a glance
- Drugs HSK 21542 (Primary)
- Indications Pruritus
- Focus Registrational; Therapeutic Use
- Sponsors Haisco Pharmaceutical Group
- 01 Dec 2021 New trial record